According to the Guangji Pharmaceutical announcement, Jikang Company, a wholly-owned subsidiary of the company, publicly listed and transferred 51% of the shares of Changjiang Guangji Company through the Wuhan Optics Valley Joint Stock Exchange, and the listing price was not lower than the registered assessed value of the corresponding shares of 19126.02 million yuan. After the listing period ended, Changjiang Medical Investment, the only eligible intended transferee, was solicited. The transaction price was 19126.02 million yuan. Changjiang Medical Investment is a wholly-owned subsidiary of Changjiang Industrial Investment Group, the controlling shareholder of the company. This transaction constitutes a related transaction. After the transaction was completed, Jikang Company held 49% of the shares in Changjiang Guangji Company, which was no longer included in the scope of the company's consolidated statements. The transaction has been reviewed and approved by the company's board of directors. There is no need to submit it to the shareholders' meeting for review, and it does not constitute a major asset restructuring.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.